Selling a Pharmacy: When the Closing Date Outran the Licence

The situation

Agnieszka and Bilal, both elementary school teachers, had owned a small independent pharmacy in Brampton for over a decade as a side investment. Neither of them was a pharmacist. They had bought the business from its founding owner early in their careers, kept a licensed pharmacist on staff to run the dispensary and manage the professional side of the business, and treated it as a second income while they kept teaching. The business, structured as a corporation that held the pharmacy's assets, lease and goodwill, was worth roughly $1.1 million by the time their long-time pharmacist-manager told them he planned to retire.

Rather than replace him and keep running the business, Agnieszka and Bilal decided to sell. Through a business broker, they found a buyer within a few months: Imran, a licensed pharmacist who had been working for a larger chain and wanted to own and operate his own location. The two sides negotiated price and terms directly with the broker's help and signed an agreement of purchase and sale using a template the broker supplied, setting a closing date about sixty days out. Only after the agreement was signed did Agnieszka and Bilal retain Treadstone Law to handle the closing itself — a common enough sequence for a straightforward asset sale, but this was not a straightforward asset sale.

What the review found

A pharmacy is not an ordinary retail business from a legal standpoint. The right to dispense prescription medication from a specific location is tied to an accreditation issued by the pharmacy regulator that governs the profession in Ontario, and that accreditation belongs to the operator, not the building or the corporate shell around it. When a pharmacy changes hands, the outgoing accreditation does not simply carry over to the new owner. The incoming operator has to apply for their own accreditation for that specific location, and the regulator typically requires supporting documentation, a site inspection, and confirmation that the new owner meets the professional and premises standards before it will issue approval. That process routinely takes longer than sixty days, and it cannot begin in earnest until the buyer has firm details of the transaction to submit.

None of this had been factored into the agreement Agnieszka and Bilal signed. The closing date had been chosen the way closing dates are chosen in most small business sales — based on when the parties wanted to be done, not on a regulator's processing timeline. When our team reviewed the file shortly after being retained, with roughly five weeks left before the scheduled closing, Imran's accreditation application had only just been submitted. On the timeline the regulator had indicated, approval was unlikely to arrive before the agreed closing date, and could realistically take several weeks beyond it.

That created a genuine problem, not a paperwork inconvenience. If the sale closed on schedule with Imran taking over as the pharmacy's registered operator before his own accreditation was issued, the pharmacy would be operating unlawfully — dispensing under an accreditation that no longer matched who actually controlled the business. If the sale simply closed late to wait for the regulator, Agnieszka and Bilal would be left operating and funding a business they had already agreed to sell, with no certainty about exactly how much longer that would last. Either path carried cost. The question was how to absorb it without the deal falling apart or either side taking on legal exposure they hadn't agreed to.

What we did

1. Flagged the gap immediately and quantified the timeline. Rather than wait to see if the regulator's process resolved on its own, we contacted the regulator's licensing staff directly to get a realistic estimate for Imran's application, and confirmed it in writing. That gave both sides a number to plan around instead of guessing.
2. Opened a direct conversation with the buyer's lawyer. Imran had retained his own counsel for the closing, and once both firms understood the accreditation timeline, the shared interest was obvious: neither side wanted the deal to fail over a regulatory delay neither of them had caused. That made negotiating a fix cooperative rather than adversarial.
3. Restructured the deal around an economic closing and a licence closing. We proposed splitting the transaction into two dates: an economic closing on the original date, where the purchase price was largely secured and risk began shifting to the buyer, and a separate licence closing once Imran's accreditation was actually issued, at which point he would formally take over as the registered operator.
4. Arranged for the outgoing pharmacist-manager to keep dispensing during the gap. Because the existing accreditation was tied to Agnieszka and Bilal's corporation and their outgoing manager, we structured a short interim operating arrangement where he continued running the dispensary under the existing licence for the bridge period, with Imran overseeing the business commercially in the background.
5. Built in a holdback and a cost-sharing formula. Rather than leave the extra weeks of payroll, insurance and overhead as an open-ended dispute, the amended agreement set out exactly how the carrying costs of the bridge period would be split, funded from a holdback against the purchase price so neither side had to chase the other for reimbursement afterward.
6. Confirmed every regulatory notice was filed correctly. The regulator requires specific notifications when a pharmacy's ownership or operator changes, on both the outgoing and incoming sides. We made sure those were filed accurately and on time, so the interim arrangement itself did not create a separate compliance problem.

The outcome

The deal closed, but not the way Agnieszka and Bilal had originally planned, and not without cost. The economic closing happened on the original date as agreed, with the bulk of the purchase price released and Imran assuming commercial control and risk. The licence closing followed about six weeks later, once his accreditation for the location came through and he could formally take over as the registered operator.

Bridging that gap was not free. The outgoing pharmacist-manager's continued wages, plus the extra weeks of overhead the business carried before the licence closing, came to roughly $22,000, split between the parties under the formula built into the amended agreement rather than absorbed entirely by one side. Imran also lost the benefit of his original financing rate lock during the delay and had to renegotiate his loan terms with his lender, adding a modest but real cost on his end. None of that was catastrophic, and none of it was reflected in the original deal Agnieszka and Bilal had signed before coming to Treadstone Law. It was avoidable cost that existed only because the closing date had been set without checking whether the regulator could move that fast.

What the restructuring avoided was worse: a collapsed sale after both sides had already committed, or a pharmacy operating for weeks without a properly accredited operator, which would have exposed Agnieszka and Bilal's corporation and Imran personally to regulatory consequences neither of them wanted. The lesson for Agnieszka and Bilal was a genuinely hard one to hear, since the added cost and the six extra weeks of running a business they had already mentally left were both preventable. Acting on the gap the moment it was identified, rather than after the closing date arrived and positions had hardened, is what kept a fixable problem from becoming an unfixable one.

What you can learn from this